Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Erik, Mannaert"'
Autor:
Annemie Deiteren, Erwin Coenen, Sabine Lenders, Peter Verwilst, Erik Mannaert, Freya Rasschaert
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2450-2460 (2021)
Abstract Protocols for clinical trials describe inclusion and exclusion criteria based on general and compound‐specific considerations to ensure subject safety and data quality. In phase I clinical trials, healthy volunteers (HVs) are screened agai
Externí odkaz:
https://doaj.org/article/4235eb3060a14b7e8e5f2d52ef5832b6
Autor:
Sandy Van Hemelryck, Jonatan Dewulf, Harm Niekus, Marjolein van Heerden, Benno Ingelse, René Holm, Erik Mannaert, Peter Langguth
Publikováno v:
International Journal of Pharmaceutics: X, Vol 1, Iss , Pp - (2019)
The objective of this study was to evaluate in vitro and in vivo drug release from in situ forming gels prepared with poloxamer 338 (P338) and/or 407 (P407) in N-methyl-2-pyrrolidone (NMP)/water mixtures for the model compound bedaquiline fumarate sa
Externí odkaz:
https://doaj.org/article/2b4dd4a7e7ba43d2bc553d923546c1c7
Autor:
Sandy Van Hemelryck, Rani Wens, Hannelore van Poppel, Milou Luijks, Koosha Shahidi, Marcin Marczak, Ariane Kahnt, René Holm, Erik Mannaert, Peter Langguth
Publikováno v:
Pharmaceutics, Vol 13, Iss 8, p 1231 (2021)
This study evaluated in vitro and in vivo drug release of bedaquiline from in situ forming gels (ISGs) containing 200 mg eq./g bedaquiline fumarate salt prepared with four different grades of poly(d,l-lactide) (PDLLA) or poly(d,l-lactide-co-glycolide
Externí odkaz:
https://doaj.org/article/2a963148dce44c2a8f2e1c01e20930bf
Autor:
Freya Rasschaert, Annemie Deiteren, Sabine Lenders, Erwin Coenen, Peter Verwilst, Erik Mannaert
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 6, Pp 2450-2460 (2021)
Clinical and Translational Science, Vol 14, Iss 6, Pp 2450-2460 (2021)
Protocols for clinical trials describe inclusion and exclusion criteria based on general and compound‐specific considerations to ensure subject safety and data quality. In phase I clinical trials, healthy volunteers (HVs) are screened against these
Autor:
René Holm, Erik Mannaert, Rani Wens, A. Kahnt, Sandy Van Hemelryck, Milou Luijks, Hannelore van Poppel, Marcin Marczak, Peter Langguth, Koosha Shahidi
Publikováno v:
Pharmaceutics
Volume 13
Issue 8
Pharmaceutics, Vol 13, Iss 1231, p 1231 (2021)
Van Hemelryck, S, Wens, R, van Poppel, H, Luijks, M, Shahidi, K, Marczak, M, Kahnt, A, Holm, R, Mannaert, E & Langguth, P 2021, ' In vitro evaluation of poly(Lactide-co-glycolide) in situ forming gels for bedaquiline fumarate salt and pharmacokinetics following subcutaneous injection in rats ', Pharmaceutics, vol. 13, no. 8, 1231 . https://doi.org/10.3390/pharmaceutics13081231
Volume 13
Issue 8
Pharmaceutics, Vol 13, Iss 1231, p 1231 (2021)
Van Hemelryck, S, Wens, R, van Poppel, H, Luijks, M, Shahidi, K, Marczak, M, Kahnt, A, Holm, R, Mannaert, E & Langguth, P 2021, ' In vitro evaluation of poly(Lactide-co-glycolide) in situ forming gels for bedaquiline fumarate salt and pharmacokinetics following subcutaneous injection in rats ', Pharmaceutics, vol. 13, no. 8, 1231 . https://doi.org/10.3390/pharmaceutics13081231
This study evaluated in vitro and in vivo drug release of bedaquiline from in situ forming gels (ISGs) containing 200 mg eq./g bedaquiline fumarate salt prepared with four different grades of poly(d,l-lactide) (PDLLA) or poly(d,l-lactide-co-glycolide
Autor:
Claire Mackie, Marcus E. Brewster, Jan Bevernage, Erik Mannaert, Sandy Van Hemelryck, Achiel Van Peer, An Van Den Bergh
Publikováno v:
Molecular Pharmaceutics. 15:2633-2645
The aim of the presented retrospective analysis was to verify whether a previously proposed Janssen Biopharmaceutical Classification System (BCS)-like decision tree, based on preclinical bioavailability data of a solution and suspension formulation,
Autor:
John R. Crison, Martin Mueller-Zsigmondy, Talia Flanagan, A. Van Peer, Mark McAllister, Uwe Muenster, Peter Timmins, Erik Mannaert, Jeike Biewenga, René Holm, Stefania Beato, S. Page, Stefaan Rossenu, Peter Langguth, Alan F. Parr, Filippos Kesisoglou, Mai Anh Nguyen, R. Li, An Vermeulen, Krista Ojala, Marcus E. Brewster
Publikováno v:
European Journal of Pharmaceutical Sciences. 102:1-13
The present work aimed to describe the current status of IVIVC/IVIVR development in the pharmaceutical industry, focusing on the use and perception of specific approaches as well as successful and failed case studies. Two questionnaires have been dis
Autor:
Benno Ingelse, René Holm, Peter Langguth, Erik Mannaert, Sandy Van Hemelryck, Jonatan Dewulf, Marjolein van Heerden, Harm Niekus
Publikováno v:
International Journal of Pharmaceutics: X
International Journal of Pharmaceutics: X, Vol 1, Iss, Pp-(2019)
International Journal of Pharmaceutics: X, Vol 1, Iss, Pp-(2019)
Graphical abstract
The objective of this study was to evaluate in vitro and in vivo drug release from in situ forming gels prepared with poloxamer 338 (P338) and/or 407 (P407) in N-methyl-2-pyrrolidone (NMP)/water mixtures for the model compound
The objective of this study was to evaluate in vitro and in vivo drug release from in situ forming gels prepared with poloxamer 338 (P338) and/or 407 (P407) in N-methyl-2-pyrrolidone (NMP)/water mixtures for the model compound
Autor:
Juthamas Sukbuntherng, James Jiao, Donna Skee, Joseph Murphy, Jan de Jong, Ronald de Vries, Loeckie de Zwart, Erik Mannaert, Maarten Vliegen, Jan Snoeys, Johan W. Smit, Peter Hellemans
Publikováno v:
British Journal of Clinical Pharmacology. 81:235-245
Aims Ibrutinib, an inhibitor of Bruton's tyrosine kinase, is used in the treatment of mantle cell lymphoma or chronic lymphocytic leukaemia. Ibrutinib undergoes extensive rapid oxidative metabolism mediated by cytochrome P450 3A both at the level of
Autor:
Juthamas Sukbuntherng, Susan O'Brien, David Loury, John C. Byrd, Peter Hellemans, Jan de Jong, Danelle F. James, Donna Skee, Joseph Murphy, Vijay Chauhan, Erik Mannaert, Juhui Jiao
Publikováno v:
Cancer chemotherapy and pharmacology, vol 75, iss 5
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose To assess ibrutinib pharmacokinetics under fasted and fed conditions, impact of food-intake timing, and the safety and tolerability. Methods Three studies were analyzed. Study 1 was a randomized, open-label, single-dose, four-way crossover st